Blood Preparation Market Size To Grow USD 81.99 Bn By 2032

The global blood preparation market size reached USD 48.53 billion in 2023 and is expected to grow around USD 81.99 billion by 2032, at a CAGR of 6% during the forecast period from 2023 to 2032.

Key Takeaways

• North America contributed more than 45% of revenue share in 2022.
• Asia Pacific is expected to witness the fastest growth rate in the blood preparation market during the forecast period.
• By product, the whole blood segment held the largest share of the blood preparation market in 2022.
• The blood derivatives segment is expected to grow at a significant compounded annual growth (CAGR) rate during the forecast period.
• By application, the thrombocytosis segment accounted for a larger share in 2022.
• The angina blood vessel complications segment is estimated to grow with a notable CAGR during the study period till 2032.

The Blood Preparation Market encompasses a diverse range of products and services aimed at ensuring the safety and efficacy of blood transfusions and related medical procedures. This sector plays a crucial role in healthcare by providing blood components, such as red blood cells, plasma, and platelets, prepared to meet specific medical requirements. The market has witnessed steady growth in recent years, driven by factors such as increasing demand for blood and blood components, advancements in blood processing technologies, and a rising emphasis on ensuring the quality of blood products.

Get a Sample: https://www.precedenceresearch.com/sample/3551

Several factors contribute to the growth of the Blood Preparation Market. Technological advancements have led to more efficient and precise methods of blood separation, storage, and testing, enhancing the overall safety of blood products. Additionally, the growing prevalence of chronic diseases and surgical procedures has increased the demand for blood transfusions, driving the need for reliable and standardized blood preparation methods. The expansion of healthcare infrastructure, especially in developing regions, further contributes to market growth by increasing access to blood preparation services.

Furthermore, the market is influenced by regulatory initiatives aimed at enhancing the safety and quality of blood products. Stringent regulations and guidelines set by health authorities push companies in the Blood Preparation Market to adopt advanced technologies and adhere to rigorous quality standards. This not only ensures patient safety but also fosters trust among healthcare professionals and patients, driving the market forward.

Blood Preparation Market Scope

Read More: Molecular Biology Enzymes Market Size, Growth, Report 2032

• By Product: The Blood Preparation Market is characterized by a range of products designed to meet different medical needs. This includes blood components such as red blood cells, plasma, platelets, and whole blood. Additionally, various blood derivatives and products like immunoglobulins, albumin, and clotting factor concentrates play a crucial role in addressing specific medical conditions.
• By Antithrombotic and Anticoagulants Type: Within the Blood Preparation Market, antithrombotic and anticoagulant agents play a pivotal role in preventing and managing blood clotting disorders. These substances are classified into different types, such as antiplatelet agents, anticoagulant drugs, and thrombolytics. Each type serves distinct therapeutic purposes, ranging from preventing arterial and venous thrombosis to dissolving existing blood clots.
• By Application: The applications of blood preparations span a broad spectrum of medical scenarios. They are extensively used in the treatment of various diseases and conditions, including cardiovascular diseases, hematological disorders, and autoimmune diseases. Furthermore, blood preparations find application in surgical procedures, trauma care, and emergency medicine, highlighting their versatility and significance in diverse healthcare settings.
• By End User: The end user segment of the Blood Preparation Market encompasses a wide array of healthcare institutions and facilities. Hospitals and clinics are primary consumers, utilizing blood preparations in routine medical procedures and emergency situations. Additionally, blood banks and diagnostic laboratories are integral end users, ensuring a stable supply of blood components for therapeutic and diagnostic purposes. The pharmaceutical industry is also a key player, involved in the development and production of blood preparation products.

Reasons to Purchase this Report:

• Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
• In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
• Market size in USD million and volume in million units provided for each segment and sub-segment.
• Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
• Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.

Recent Developments

• In May 2023, with $50 million from the New York Blood Center, NYBC Ventures was unveiled as one of the first venture funds focusing exclusively on advancing new blood and cell-based therapies. Thus, increasing funds for new blood and cell-based therapies is expected to contribute to the promising growth of the blood preparation market.
• In February 2023, Terumo Blood and Cell Technologies announced the FDA clearance and official launch of its IMUGARD® WB Platelet Pooling Set. This new platelet pooling set supports extended shelf life of whole blood-derived platelets from 5 to 7 days. IMUGARD is the first platelet pooling set approved for 7-day storage in the United States.
• In November 2022, the RESTORE clinical trial (REcovery and survival of STem cell Originated REd cells) was initiated by the NIHR Blood and Transplant Research Unit. Researchers stated that if this clinical trial of lab-grown red blood cells is proven effective and safe, it can revolutionize treatments for people with rare blood types.

Blood Preparation Market Players

• AstraZeneca plc
• Baxter International Inc
• Bristol-Myers Squibb Company
• Celgene Corp.
• GlaxoSmithKline PLC
• Leo Pharma A/S
• Pfizer, Inc.
• Portola Pharmaceuticals, Inc.
• Sanofi
• Shandong East Chemical Industry Co.
• Xiamen Hisunny Chemical Co., LTD

Segments Covered in the Report

By Product

• Whole blood
  • Granulocytes
  • Red blood cells
  • Plasma
  • Platelets
• Blood components
  • Leukocyte reduced red blood cells
  • Packed red blood cells
  • Frozen plasma
  • Platelet concentrates
  • Cryoprecipitate
• Blood derivatives

By Antithrombotic and Anticoagulants Type

• Platelet aggregation inhibitors
  • Glycoprotein inhibitors
  • ADP antagonists
  • COX inhibitors
  • Others
• Fibrinolytics
  • Streptokinase
  • Tissue plasminogen activator (tPA)
  • Urokinase
• Anticoagulants
  • Heparins
    • Low molecular weight heparin (LMWH)
    • Unfractionated heparin
    • Ultra-low molecular weight heparin
  • Direct thrombin inhibitors
  • Vitamin K antagonists
  • Direct factor Xa inhibitors

By Application

• Thrombocytosis
• Renal impairment
• Pulmonary embolism
• Angina blood vessel complications
• Others

By End User

• Clinics
• Hospitals
• Diagnostic centers
• Research labs
• Blood banks

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Blood Preparation Market 

5.1. COVID-19 Landscape: Blood Preparation Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Blood Preparation Market, By Product

8.1. Blood Preparation Market Revenue and Volume Forecast, by Product, 2023-2032

8.1.1. Whole blood

8.1.1.1. Market Revenue and Volume Forecast (2020-2032)

8.1.2. Blood components

8.1.2.1. Market Revenue and Volume Forecast (2020-2032)

8.1.3. Blood derivatives

8.1.3.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 9. Global Blood Preparation Market, By Antithrombotic and Anticoagulants Type

9.1. Blood Preparation Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type, 2023-2032

9.1.1. Platelet aggregation inhibitors

9.1.1.1. Market Revenue and Volume Forecast (2020-2032)

9.1.2. Fibrinolytics

9.1.2.1. Market Revenue and Volume Forecast (2020-2032)

9.1.3. Anticoagulants

9.1.3.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 10. Global Blood Preparation Market, By Application 

10.1. Blood Preparation Market Revenue and Volume Forecast, by Application, 2023-2032

10.1.1. Thrombocytosis

10.1.1.1. Market Revenue and Volume Forecast (2020-2032)

10.1.2. Renal impairment

10.1.2.1. Market Revenue and Volume Forecast (2020-2032)

10.1.3. Pulmonary embolism

10.1.3.1. Market Revenue and Volume Forecast (2020-2032)

10.1.4. Angina blood vessel complications

10.1.4.1. Market Revenue and Volume Forecast (2020-2032)

10.1.5. Others

10.1.5.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 11. Global Blood Preparation Market, By End User 

11.1. Blood Preparation Market Revenue and Volume Forecast, by End User, 2023-2032

11.1.1. Clinics

11.1.1.1. Market Revenue and Volume Forecast (2020-2032)

11.1.2. Hospitals

11.1.2.1. Market Revenue and Volume Forecast (2020-2032)

11.1.3. Diagnostic centers

11.1.3.1. Market Revenue and Volume Forecast (2020-2032)

11.1.4. Research labs

11.1.4.1. Market Revenue and Volume Forecast (2020-2032)

11.1.5. Blood banks

11.1.5.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 12. Global Blood Preparation Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.1.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.1.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.1.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.1.5.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.1.5.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.1.5.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.1.6.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.1.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.1.6.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.2.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.2.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.2.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.2.5.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.2.5.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.2.5.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.2.6.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.2.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.2.6.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.2.7.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.2.7.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.2.7.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.2.8.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.2.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.2.8.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.3.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.3.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.3.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.3.5.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.3.5.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.3.5.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.3.6.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.3.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.3.6.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.3.7.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.3.7.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.3.7.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.3.8.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.3.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.3.8.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.4.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.4.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.4.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.4.5.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.4.5.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.4.5.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.4.6.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.4.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.4.6.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.4.7.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.4.7.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.4.7.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.4.8.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.4.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.4.8.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.5.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.5.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.5.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.5.5.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.5.5.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.5.5.4. Market Revenue and Volume Forecast, by End User (2020-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)

12.5.6.2. Market Revenue and Volume Forecast, by Antithrombotic and Anticoagulants Type (2020-2032)

12.5.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)

12.5.6.4. Market Revenue and Volume Forecast, by End User (2020-2032)

Chapter 13. Company Profiles

13.1. AstraZeneca plc

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Baxter International Inc

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Bristol-Myers Squibb Company

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Celgene Corp.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. GlaxoSmithKline PLC

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Leo Pharma A/S

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Pfizer, Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Portola Pharmaceuticals, Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Sanofi

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Shandong East Chemical Industry Co.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/

---